Exciting to share that UNIKUM Therapeutics is presenting our preclinical development program PIRC100 at ESGCT. If you want to know more about our program and path toward the clinic with the first-in-class "programmable immune reactive cell" therapy, then come and listen to principal Scientist Anders Laustsen and meet our CSO Iulia Diaconu and scientific co-founder Rasmus O. Bak
About us
Unikum Therapeutics is an early stage biotech company currently located in Denmark. It was spun out from the Department of Biomedicine at Aarhus University in 2020. It’s founded on the breakthrough discovery on how to manufacture a specific type of innate immune cells, namely plasmacytoid Dendritic Cells (pDCs) for use in cellular therapies, including cancer immunotherapy. pDCs are multifaceted immune cells with features that have been lacking in existing therapies. UNIKUM Therapeutics has developed methods to genetically engineer the cells, thereby further enhancing their therapeutic potential and establishing a unique position to champion a whole new class of cellular therapies. The company is funded by the Creation House program at the BioInnovation Institute and the Innobooster program from the Innovation Fund Denmark.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
Employees at UNIKUM Therapeutics
-
Iulia Diaconu
Chief Scientific Officer
-
Ulrik B. Nielsen
Disruptive medicines entrepreneur, investor, and board member
-
Rasmus O. Bak
Associate Professor (tenured) at Aarhus University
-
Martin Roelsgaard Jakobsen
Professor in infection and immunology | biotech entrepreneur | Scientific consultant | BoD member
Updates
-
Interested in Novel Cell Therapy and biotech in Copenhagen, DK? Are you a senior scientist with the right competences? Then read Unikum Tx new job post Deadline 30th of June 2024 #biotech #celltherapy #innovation #Copenhagen #genetherapy #cancer #immunotherapy #lifescience #job #jobposition #jobalert #nowhiring #recruiting #jobsearch #jobsearching #jobseekers #hire
-
Our CSO Iulia Diaconu will be presenting at Immuno-Oncology Summit in London the 23-25th of April. Come by and have a talk with her or our scientific founder Professor Martin R Jakobsen about Unikum Therapeutic cell therapy platform #IOSummitUK
-